🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Neuroendocrine Neoplasm

A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors NCT06936735Phase 11 site📍 Shanghai Hansoh BioMedical R&D Company · Tests: HS-20108 Monotherapy A Study of IBI363 in Subjects With Advanced Melanoma NCT06081920Phase 212 sites📍 Beijing📍 Beijing📍 Fuzhou Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI363 A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC NCT07416695Phase 12 sites📍 Beijing📍 Shanghai Shanghai Henlius Biotech · Tests: HLX3901 Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma NCT07627698Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors NCT06038461Phase 1, Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Surufatinib Combined With Temozolomide and S-1 A Study of TRK-950 in Patients With Advanced Solid Tumors NCT05423262Phase 1, Phase 210 sites📍 Nagoya📍 Fukuoka📍 Sapporo Toray Industries, Inc · Tests: TRK-950, TRK-950, TRK-950, Nivolumab, TRK-950 To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma NCT06204991Phase 12 sites📍 Herlev📍 Herlev Inge Marie Svane · Tests: ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate, Proleukin Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors NCT06938880Phase 1, Phase 21 site📍 Guangzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZGGS18 for Injection, ZG005 for Injection Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study NCT07050940NA5 sites📍 Bari📍 Torino📍 Bari Azienda Ospedaliera di Perugia · Tests: Postbiotic, AntiPD1 A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680Phase 258 sites📍 San Francisco📍 Aurora📍 Atlanta Bristol-Myers Squibb · Tests: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) NCT06141369NA1 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: individualized mRNA neoantigen vaccine (mRNA-0523-L001) A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Avapritinib A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma NCT06472661EARLY Phase 11 site📍 Charlottesville University of Virginia · Tests: Echopulse or Echopulse HD, PolyICLC Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site📍 Jinan Mainline Biosciences (Shanghai) Co., Ltd · Tests: MB0151 for injection A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma NCT05607095Phase 12 sites📍 Harrison📍 New York Memorial Sloan Kettering Cancer Center · Tests: Lifileucel (LN-144/LN-145) Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT07038096Phase 1, Phase 21 site📍 Guanzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG006, ZG005 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer NCT06636435Phase 15 sites📍 Kashiwa📍 Yokohama📍 Niigata Chiome Bioscience Inc. · Tests: CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4, CBA-1205 Part 5 IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Neoadjuvant Tebentafusp for Uveal Melanoma NCT06414590Phase 22 sites📍 Philadelphia📍 Philadelphia Thomas Jefferson University · Tests: Tebentafusp-Tebn
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy